ARZERRA

Arzerra Adverse Events Reported to the FDA Over Time

How are Arzerra adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Arzerra, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Arzerra is flagged as the suspect drug causing the adverse event.

Most Common Arzerra Adverse Events Reported to the FDA

What are the most common Arzerra adverse events reported to the FDA?

Death	18 (2.36%)
Dyspnoea	18 (2.36%)
Infusion Related Reaction	17 (2.23%)
Neutropenia	17 (2.23%)
Pyrexia	17 (2.23%)
Pneumonia	16 (2.1%)
Rash	14 (1.83%)
Febrile Neutropenia	13 (1.7%)
Neuropathy Peripheral	12 (1.57%)
Disease Progression	11 (1.44%)
Urticaria	11 (1.44%)
	Show More
Diarrhoea	10 (1.31%)
Nausea	10 (1.31%)
Pruritus	10 (1.31%)
Chest Pain	9 (1.18%)
Lymphadenopathy	9 (1.18%)
Platelet Count Decreased	9 (1.18%)
Thrombocytopenia	9 (1.18%)
Anaemia	8 (1.05%)
Sepsis	8 (1.05%)
Chronic Lymphocytic Leukaemia	7 (.92%)
Vomiting	7 (.92%)
Asthenia	6 (.79%)
Flushing	6 (.79%)
Hyperhidrosis	6 (.79%)
Neutrophil Count Decreased	6 (.79%)
Weight Decreased	6 (.79%)
White Blood Cell Count Decreased	6 (.79%)
Adverse Drug Reaction	5 (.66%)
Chills	5 (.66%)
Fatigue	5 (.66%)
Hypoaesthesia	5 (.66%)
Local Swelling	5 (.66%)
Tremor	5 (.66%)
Abdominal Pain Upper	4 (.52%)
Bradycardia	4 (.52%)
Cardiac Arrest	4 (.52%)
Deep Vein Thrombosis	4 (.52%)
Dizziness	4 (.52%)
Drug Administration Error	4 (.52%)
Erythema	4 (.52%)
General Physical Health Deteriorati...	4 (.52%)
Off Label Use	4 (.52%)
Oxygen Saturation Decreased	4 (.52%)
Pain In Extremity	4 (.52%)
Rash Vesicular	4 (.52%)
Throat Tightness	4 (.52%)
White Blood Cell Count Increased	4 (.52%)
Abdominal Discomfort	3 (.39%)
Alanine Aminotransferase Increased	3 (.39%)
Back Pain	3 (.39%)
Blister	3 (.39%)
Blood Bilirubin Increased	3 (.39%)
Cellulitis	3 (.39%)
Cough	3 (.39%)
Drug Ineffective	3 (.39%)
Electrocardiogram Qt Prolonged	3 (.39%)
Enterococcal Sepsis	3 (.39%)
Escherichia Sepsis	3 (.39%)
Feeling Hot	3 (.39%)
Gait Disturbance	3 (.39%)
Hepatic Enzyme Increased	3 (.39%)
Hepatitis B	3 (.39%)
Hepatomegaly	3 (.39%)
Hepatorenal Syndrome	3 (.39%)
Herpes Virus Infection	3 (.39%)
Hypertension	3 (.39%)
Infection	3 (.39%)
Liver Function Test Abnormal	3 (.39%)
Lymphocyte Count Increased	3 (.39%)
Lymphoma	3 (.39%)
Pancytopenia	3 (.39%)
Paraesthesia	3 (.39%)
Paraesthesia Oral	3 (.39%)
Product Quality Issue	3 (.39%)
Productive Cough	3 (.39%)
Progressive Multifocal Leukoencepha...	3 (.39%)
Throat Irritation	3 (.39%)
Acute Respiratory Distress Syndrome	2 (.26%)
Adenovirus Infection	2 (.26%)
Anosmia	2 (.26%)
Arrhythmia	2 (.26%)
Arthralgia	2 (.26%)
Ascites	2 (.26%)
Balance Disorder	2 (.26%)
Basal Cell Carcinoma	2 (.26%)
Blood Glucose Increased	2 (.26%)
Bone Pain	2 (.26%)
Burning Sensation	2 (.26%)
C-reactive Protein Increased	2 (.26%)
Cerebrovascular Accident	2 (.26%)
Chest Discomfort	2 (.26%)
Coagulopathy	2 (.26%)
Cognitive Disorder	2 (.26%)
Colitis	2 (.26%)
Coma Hepatic	2 (.26%)
Confusional State	2 (.26%)
Dehydration	2 (.26%)
Delirium	2 (.26%)
Diabetes Mellitus	2 (.26%)
Ear Infection	2 (.26%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Arzerra, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Arzerra is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Arzerra

What are the most common Arzerra adverse events reported to the FDA?

Infections - Pathogen Unspecified	44 (5.77%)
Hematology Investigations	42 (5.5%)
Respiratory	42 (5.5%)
Epidermal And Dermal Conditions	39 (5.11%)
White Blood Cell	32 (4.19%)
Gastrointestinal Signs	28 (3.67%)
Neurological	24 (3.15%)
Administration Site Reactions	20 (2.62%)
Body Temperature Conditions	18 (2.36%)
Fatal Outcomes	18 (2.36%)
Cardiac Arrhythmias	17 (2.23%)
	Show More
Medication Errors	15 (1.97%)
Viral Infectious	15 (1.97%)
Hepatobiliary	14 (1.83%)
Bacterial Infectious	13 (1.7%)
Gastrointestinal Motility And Defec...	13 (1.7%)
Hepatic And Hepatobiliary	13 (1.7%)
Peripheral Neuropathies	12 (1.57%)
Anemias Nonhemolytic And Marrow Dep...	11 (1.44%)
Angiedema And Urticaria	11 (1.44%)
Leukemias	11 (1.44%)
Spleen, Lymphatic And Reticulendoth...	11 (1.44%)
Cardiac And Vascular Investigations	10 (1.31%)
Musculoskeletal And Connective Tiss...	10 (1.31%)
Therapeutic And Nontherapeutic Effe...	10 (1.31%)
Electrolyte And Fluid Balance Condi...	9 (1.18%)
Platelet	9 (1.18%)
Embolism And Thrombosis	7 (.92%)
Metabolic, Nutritional And Blood Ga...	7 (.92%)
Skin Appendage Conditions	7 (.92%)
Lower Respiratory Tract Disorders	6 (.79%)
Oral Soft Tissue Conditions	6 (.79%)
Physical Examination Topics	6 (.79%)
Renal Disorders	6 (.79%)
Vascular	6 (.79%)
Movement Disorders	5 (.66%)
Deliria	4 (.52%)
Miscellaneous And Site Unspecified ...	4 (.52%)
Therapeutic Procedures And Supporti...	4 (.52%)
Upper Respiratory Tract Disorders	4 (.52%)
Allergic Conditions	3 (.39%)
Aural	3 (.39%)
Fungal Infectious	3 (.39%)
Gastrointestinal Stenosis And Obstr...	3 (.39%)
Investigations, Imaging And Histopa...	3 (.39%)
Joint	3 (.39%)
Lymphomas	3 (.39%)
Mental Impairment	3 (.39%)
Microbiology And Serology	3 (.39%)
Muscle	3 (.39%)
Neurological, Special Senses And Ps...	3 (.39%)
Product Quality Issues	3 (.39%)
Protein And Chemistry Analyses	3 (.39%)
Psychiatric	3 (.39%)
Vascular Hypertensive	3 (.39%)
Bone Disorders	2 (.26%)
Bronchial Disorders	2 (.26%)
Central Nervous System Vascular	2 (.26%)
Coagulopathies And Bleeding Diathes...	2 (.26%)
Coronary Artery	2 (.26%)
Cranial Nerve Disorders	2 (.26%)
Decreased And Nonspecific Blood Pre...	2 (.26%)
Encephalopathies	2 (.26%)
Exocrine Pancreas Conditions	2 (.26%)
Eye	2 (.26%)
Gastrointestinal Inflammatory Condi...	2 (.26%)
Glucose Metabolism Disorders	2 (.26%)
Hemolyses And Related Conditions	2 (.26%)
Hepatobiliary Neoplasms Malignant A...	2 (.26%)
Immunodeficiency Syndromes	2 (.26%)
Injuries	2 (.26%)
Lifestyle Issues	2 (.26%)
Metastases	2 (.26%)
Peritoneal And Retroperitoneal Cond...	2 (.26%)
Pulmonary Vascular	2 (.26%)
Red Blood Cell	2 (.26%)
Renal And Urinary Tract Investigati...	2 (.26%)
Skin Neoplasms Malignant And Unspec...	2 (.26%)
Urinary Tract Signs	2 (.26%)
Vascular Hemorrhagic	2 (.26%)
Vision	2 (.26%)
Anxiety Disorders	1 (.13%)
Appetite And General Nutritional	1 (.13%)
Bone And Joint Injuries	1 (.13%)
Bone, Calcium, Magnesium And Phosph...	1 (.13%)
Cardiac Disorder Signs	1 (.13%)
Enzyme	1 (.13%)
Gastrointestinal Conditions	1 (.13%)
Headaches	1 (.13%)
Heart Failures	1 (.13%)
Hematopoietic Neoplasms	1 (.13%)
Immune	1 (.13%)
Inner Ear And Viiith Cranial Nerve	1 (.13%)
Lymphomas Non-hodgkins B-cell	1 (.13%)
Mood Disorders	1 (.13%)
Myocardial	1 (.13%)
Ocular Hemorrhages And Vascular	1 (.13%)
Structural Brain	1 (.13%)
Water, Electrolyte And Mineral	1 (.13%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Arzerra, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Arzerra is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.